https://www.selleckchem.com/products/icg-001.html
predict patient outcome regarding distant recurrences. To evaluate HER2-negative breast cancer (BC) with a low hormone receptor (HR) expression, with regard to pathological complete response (pCR) and survival, in comparison to triple-negative BC (TNBC) and strong HR-positive BC. We compared negative [oestrogen (ER) and progesterone receptor (PR) 1%], low-positive (ER and/or PR 1-9%)and strong-positive (ER or PR 10-100%) HR-expression in neoadjuvant clinical trial cohorts (n=2765) of BC patients. End-points were disease-free surviva
Like
Comment
Share
